

B1 cont.
CD11d/CD18 integrins or their ligands and which block the interaction of the CD11d/CD18
integrins or their ligands with vascular cells; molecules which inhibit expression of the
CD11d/CD18 integrins or their ligands, and peptides and peptidomimetics derived from the
CD11d/CD18 integrins or their ligands which block the interaction of the CD11d/CD18 integrins
or their ligands with vascular cells or tissues, in an amount effective to inhibit or reduce stenosis
or dependent restenosis of a blood vessel following injury to vascular tissue.

B2
5. (amended) The method of claim 1 wherein the CD11d/CD18 integrin is selected
from the group consisting of Mac-1, LFA-1, and p150,95[, and CD11d/CD18].

6. (amended) The method of claim 5 wherein the CD11d/CD18 integrin is Mac-1.

B3
8. (amended) The method of claim 1 wherein the compound is selected from the
group consisting of antibodies and antibody fragments that are immunoreactive with
CD11d/CD18 integrins or their ligands and which block the interaction of the CD11d/CD18
integrins or their ligands with vascular cells[; molecules which inhibit expression of the
CD11d/CD18 integrins or their ligands, and peptides and peptidomimetics derived from the
CD11d/CD18 integrins or their ligands which block the interaction of the CD11d/CD18 integrins
or their ligands with vascular cells or tissues].

9. (amended) The method of claim 5 wherein the CD11d/CD18 integrin is LFA-1
and the ligand is selected from the group consisting of ICAM-1, ICAM-2, ICAM-3.

Remarks

Rejections under 35 U.S.C. §112

Claims 1-6, 8, 11 and 12 were rejected under 35 U.S.C. §112 as non-enabled. This